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ABSTRACT 
Objectives: Electrical muscle stimulation (EMS) is widely used to enhance lower limb mobilization. 
Although upper limb muscle atrophy is common in critically ill patients, EMS application for the upper 
limbs has been rarely reported. The purpose of this study was to investigate whether EMS prevents 
upper and lower limb muscle atrophy and improves physical function. 
Design: Randomized controlled trial. 
Setting: Two-center, mixed medical/surgical intensive care unit (ICU). 
Patients: Adult patients who were expected to be mechanically ventilated for >48 h and stay in the ICU 
for >5 days. 




Measurements and Main Results: Primary outcomes were change in muscle thickness and cross-
sectional area of the biceps brachii and rectus femoris from day 1 to 5. Secondary outcomes included 
incidence of ICU-acquired weakness (ICU-AW), ICU mobility scale (IMS), length of hospitalization, 
and amino acid levels. The change in biceps brachii muscle thickness was −1.9% vs. −11.2% in the 
EMS and control (p = 0.007) groups, and the change in cross-sectional area was −2.7% vs. −10.0% (p = 
0.03). The change in rectus femoris muscle thickness was −0.9% vs. −14.7% (p = 0.003) and cross-
sectional area was −1.7% vs. −10.4% (p = 0.04). No significant difference was found in ICU-AW (13% 
vs. 40%; p = 0.20) and IMS (3 vs. 2; p = 0.42) between the groups. The length of hospitalization was 
shorter in the EMS group (23 [19–34] vs. 40 [26–64] days) (p = 0.04). On day 3, the change in the 
branched-chain amino acid level was lower in the EMS group (40.5% vs. 71.5%; p = 0.04). 
Conclusion: In critically ill patients, EMS prevented upper and lower limb muscle atrophy and 
attenuated proteolysis and decreased the length of hospitalization. 
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Skeletal muscle atrophy and physical disability are common in critically ill patients. Muscle 
atrophy rapidly occurs after admission to the intensive care unit (ICU), and muscle atrophy reaches 
18.8%–20.7% in the lower limbs within 7 days (1). Although most studies have evaluated lower limb 
muscle atrophy, our previous study revealed that upper limb muscle mass decreased by 13.2%–16.9% 
within 7 days of ICU admission (2). Functional disability also occurs in both the upper and lower limbs 
in ICU-acquired weakness (ICU-AW), which is found in nearly 50% of critically ill patients (1). 
Early mobilization in the ICU is proven to be effective in preventing muscle atrophy and 
physical disability. However, it is not necessarily applicable in all patients. Hence, electrical muscle 
stimulation (EMS) has been used as an additional physical therapy for critically ill patients (3). 
Previous studies showed that EMS prevented lower limb muscle atrophy in critically ill patients (4, 5) 
but did not improve physical function and mobility at discharge from the ICU (6). Lower limb EMS did 
not decrease the length of ICU and overall hospitalization (7, 8). EMS is usually used for lower limb 
training to enhance mobilization; we believed that its application to only the lower limbs was the cause 
of patients’ unchanged physical condition and morbidity level. 
  Upper limbs play an important role for maneuvers on the bed, rib cage movements, and 
mobilization ability. However, investigations on the effects of upper limb rehabilitation on muscle 
atrophy and physical function in critically ill patients are limited. To our knowledge, no randomized 
controlled trial has investigated the effects of upper limb EMS on muscle atrophy in critically ill 
patients. We hypothesized that early application of EMS on the bilateral upper and lower limbs prevents 
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upper and lower limb muscle atrophy and improves physical function and mobility level. 
 
MATERIALS AND METHODS 
Study design 
This single-blind, randomized controlled trial conducted in the mixed medical/surgical ICUs of 
Tokushima University Hospital and Tokushima Prefectural Central Hospital between July 2017 and 
January 2020 was approved by both clinical research ethics committees (approval numbers 2849 and 
1740, respectively). This study was registered as a clinical trial (UMIN Clinical Trials Registry: 
000027054). At the time of enrollment, written informed consent was obtained from patients or their 
authorized surrogate decision makers. Patients were randomly assigned to the EMS group (EMS 
application in addition to mobilization protocol) or control group (mobilization protocol alone) using 




We enrolled consecutive adult patients who were expected to be mechanically ventilated for 
>48 h and to stay in the ICU for >5 days. Patients were prospectively recruited within 24 h following 
ICU admission on weekdays. Patients who met the following criteria were excluded: age under 18 
years, trauma or amputation of upper and lower limbs, diagnosis of primary neuromuscular disease, 
systolic blood pressure <80 mmHg even with inotropic or vasopressor support, heart rate <40 or >140 
6 
 
beats/min, and peripheral oxygen saturation <88% with ventilatory support. 
 
Mobilization program 
Patients in both groups were mobilized using the same progressive mobilization protocol 
described by Morris et al. (9). The same protocol was used by the two centers in this study. Within 5 
days of intervention, the median ICU mobility scale (IMS) level of all patients was 1 (1–3) in both 
groups. 
 
Electrical muscle stimulation 
EMS was applied in addition to the mobilization program in the EMS group. EMS was 
performed using a stimulator (Solius, Minato Medical Science, Co., Ltd., Osaka, Japan). A square wave 
on the positive side (650 μS) and an exponential decay wave on the negative side were applied. The 
frequency was 20 Hz (200 Hz only at the start of energization). EMS was continuously applied for 30 
min with the cycle 400 mS “on” and 600 mS “off.” The 4-channel EMS stimulated four muscle groups 
simultaneously using eight electrodes. Rectangular electrodes (40 × 80 mm) were attached to the motor 
points of the biceps brachii and rectus femoris muscles. The motor points were identified by scanning 
the skin surface where current resulted in maximal muscle contraction. An image of the intervention 
was shown in a previous report (1). The EMS group received daily EMS sessions for 30 min from day 1 
to day 5. The output current was adjusted to ensure visible contraction of muscles. The EMS intensities 
used were 30 mAp (23–37 mAp) for the biceps brachii and 41 mAp (33–50 mAp) for the rectus 
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femoris. Compliance of protocol was 80% (60%–100%) through stimulation sessions (EMS 
sessions/study days). We did not use a sham control group because muscle contraction was apparent in 
the EMS group. 
 
Ultrasound measurement 
Muscle mass of the biceps brachii and rectus femoris muscles was evaluated by measuring the 
muscle thickness and cross-sectional area using ultrasound on day 1 and day 5. Two investigators (N.N. 
and Y.U.) performed the measurements. Measurement was performed three times with the median value 
used for evaluation. Intra-observer and inter-observer correlation coefficients ranged from 0.98 to 0.99 
(Table S1). The investigators conducting the measurements were not blinded to patients’ assignment, 
but image analyses were blinded by concealing patients’ status as previously reported (10, 11). 
 
Physical assessment 
In awake and attentive patients, the Medical Research Council (MRC) score and ICU-AW were 
evaluated at day 5 by physical therapists blinded to the randomization group (12). ICU-AW was defined 
as an MRC score of <48 on two separate occasions, and patients with preadmission MRC score of <48 
were excluded (13). IMS is a scale of mobilization capabilities from 0 (lying in bed) to 10 (walking 
independently) (14). IMS was also assessed at the time of discharge from the ICU. 
 
Amino acid level 
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Amino acid levels in whole blood were measured to evaluate proteolysis. We used metabolome 
analysis using capillary electrophoresis time-of-flight mass spectrometry (CE-TOF-MS: Agilent 
Technologies, Santa Clara, CA, USA). One milliliter of blood was collected from an arterial line when 
available. Level of all 20 amino acids were measured. Because they are important components of 
muscles, we also measured the percentage increase or decrease in branched-chain amino acid (BCAA) 
levels, including valine, leucine, and isoleucine, from day 1 to day 3 or 5. 
 
Outcome 
The primary outcomes were change in muscle thickness and cross-sectional area of the biceps 
brachii and rectus femoris muscles from day 1 to 5. To assess changes in muscle mass, we calculated 
the muscle atrophy rate, defined as the percent variation in muscle mass compared with the values at 
admission. The secondary outcomes were MRC score and ICU-AW incidence at day 5, IMS at 
discharge from the ICU, ventilator- and ICU-free days, length of hospitalization, and percentage change 
in amino acid level. 
 
Sample size and statistical analyses 
Sample size was calculated using the method described by Gerovasili et al. (4), who reported 
that EMS prevented 5.9 ± 5.1% lower limb muscle atrophy within 7 days. We hypothesized a 4.2% 
difference in the upper limb muscle mass within 5 days, with 3.7% standard deviation (SD), and aimed 
to obtain a sample size in which such a difference could be observed with alpha 0.05 and power 90%, 
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which yielded 35 patients. Assuming that 15% of patients were discharged from the ICU within 5 days, 
a total of 42 patients were needed. 
Changes in muscle mass were presented as mean and standard error of the mean. Other 
continuous data were presented as mean ± SD or median (IQR), whereas categorical data were 
expressed as number (%). Normally distributed continuous variables were compared between groups 
using the t-test, whereas non-normally distributed variables were compared using the Wilcoxon rank-
sum test. Categorical data were compared using the chi-squared test. All statistical tests were two-tailed, 
and p < 0.05 was considered statistically significant. Statistical analyses were performed using JMP 
statistical software, version 13.1.0 (SAS Institute Inc., Cary, NC, USA). 
 
RESULTS 
A total of 42 patients were enrolled, and 6 were excluded (death until day 5, rejection due to 
pain, and insufficient muscle contraction due to edema or obesity). Finally, we assigned 17 patients to 
the EMS group and 19 to the control group (Fig. 1). Mean age was 73 ± 3 vs. 66 ± 3 years (p = 0.09) 
and median acute physiology and chronic health evaluation II (APACHE II) score was 25 (20–31) vs. 
22 (19–30) (p = 0.57) in the EMS and control groups, respectively (Table 1). 
 
Changes in upper and lower limb muscle mass 
The changes in upper limb muscle thickness were −1.9 ± 2.4% and −11.2 ± 2.1% in the EMS 
and control groups, respectively (p = 0.007), and changes in cross-sectional area were −2.7 ± 2.6% and 
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−10.0 ± 1.5% in the EMS and control groups, respectively (p = 0.03) (Fig. 2). Changes in lower limb 
muscle thickness were −0.9 ± 3.1% and −14.7 ± 2.7% in the EMS and control groups, respectively (p = 
0.003), and changes in cross-sectional area were −1.7 ± 2.9% and −10.4 ± 2.8% in the EMS and control 
groups, respectively (p = 0.04). 
 
Secondary outcomes 
Physical function was assessed in 8 and 10 patients in the EMS and control groups, 
respectively. No significant difference was found in MRC score, ICU-AW incidence, and IMS at 
discharge from the ICU (Table 2). The EMS group had a shorter length of hospitalization. BCAA levels 
on day 3 were significantly lower in the EMS group than in the control group. Moreover, glycine levels 




We found that EMS of the upper and lower limb muscles prevented muscle atrophy. To our 
knowledge, this is the first study demonstrating that EMS prevented upper and lower limb muscle 
atrophy simultaneously. This study did not reveal any differences in physical function. However, we 
found that EMS attenuated proteolysis and reduced the length of hospitalization. 
Most studies apply EMS to the lower limbs, and we found one study in which EMS was 
applied to the hemilateral side of the upper and lower limbs in 14 patients (15). They reported unclear 
11 
 
results that patients exhibited significant muscle atrophy in the limb without EMS, but EMS 
intervention did not show significant differences on the stimulated or unstimulated side. This muscle 
mass measurement is based on arm circumference and muscle thickness measured by ultrasound, which 
are easily affected by edema and the angle of the legs (16-18). In contrast, cross-sectional area is more 
precise and accurate or at least less susceptible to measurement bias (19). Hence, in our study, we 
assessed muscle atrophy using cross-sectional area and not muscle thickness. 
A recent large-scale study by Fossat el al. demonstrated that rectus femoris muscle thickness 
did not change between patients with or without EMS during ICU stay (6). This study is also based on 
the measurement of muscle thickness, similar to most studies (4, 15, 17, 20). Moreover, the timing of 
intervention in the study by Fossat et al. is clearly different from that in our study. We intervened only 
in the early phase, when patients’ mobilization could not be actively performed, achieving a maximum 
IMS level of 1 during the first 5 days. In contrast, Fossat et al. intervened from ICU admission to 
discharge and actively conducted mobilization in the intervention period. EMS is less useful once 
patients are actively mobilized (3). EMS was also effective for patients whose mobilization was limited 
due to impaired consciousness or mechanical ventilation (5, 21). EMS can be used as an additional 
therapy to maintain muscle mass in this population. 
 Although our study involved both the upper and lower limbs, our results were consistent with 
those of a previous large-scale study that showed that EMS did not improve physical function and 
mobility at discharge from the ICU (6). There are several possible reasons for this. First, the number of 
included patients was insufficient to analyze physical functions. Physical assessment could be 
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performed in only 50% of included patients because of impaired consciousness. Second, we did not 
include patients requiring prolonged ICU stay. In a previous study, Silva et al. reported that 14 days 
were needed to treat muscle weakness using EMS. Our study aimed at maintaining muscle mass during 
the early phase of critical illness, and we did not include patients requiring prolonged ICU stay (21). 
Therefore, our treatment duration may not have been long enough to improve clinical outcomes. Third, 
although we applied EMS on both upper and lower limbs, the effect of muscle stimulation was limited 
to the biceps brachii and rectus femoris muscles. It was better but not feasible to stimulate all muscles. 
Our results indicate that maintaining muscle mass during the early phase of critical illness may 
reduce the length of hospitalization. In a previous study, enhanced rehabilitation of mechanically 
ventilated patients reduced the length of hospitalization (22). We believe that maintaining upper limb 
muscle mass smoothly led to mobilization because the upper limbs contribute to the ability to transfer 
from a bed to a wheelchair, to sit up, and to lie down. Furthermore, upper limbs are important for 
writing, drinking, and eating. Sufficient upper limb function may prevent aspiration or other problems 
in the ward and may reduce the length of hospitalization. Most studies applied EMS only to the lower 
limbs and did not report reduced length of hospitalization (7, 8). The simultaneous application of EMS 
to the upper limb may change the clinical outcomes of critically ill patients. 
  In critically ill patients, muscle atrophy occurs in the diaphragm and rib cage muscles as well 
as limbs. We previously reported intercostal muscle atrophy in mechanically ventilated patients, which 
was associated with weaning difficulties (10). In another study, the pectoralis major muscle was 
associated with a high 6-month survival rate (23). Upper limbs play some role in respiration in terms of 
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rib cage expansion. Therefore, our results indicate that EMS application may enhance respiratory 
muscle training. A recent study showed that EMS application to the diaphragm was feasible (24). A 
pilot study applied EMS to the abdominal muscles to assist in weaning from mechanical ventilation and 
found that the intervention decreased the duration of mechanical ventilation use (25). Moreover, upper 
limb training indirectly improves pulmonary function (26). In patients with chronic obstructive 
pulmonary disease, 8-week upper limb training improved lung function and functional capacity (27). 
Additional clinical studies will be needed to prove if EMS application to the upper limbs reduces 
mechanical ventilation time. 
 Interestingly, EMS not only prevented muscle atrophy but also attenuated proteolysis in 
critically ill patients. A previous study showed that EMS attenuated protein degradation, as evidenced 
by decreased 3-methylhistidine levels (28). In this study, we found lower BCAA levels in patients in the 
EMS group. BCAA is an important component of muscles (29). Lower BCAA levels may reflect 
decreased level of catabolism or increased consumption for protein synthesis in the muscles as 
previously reported (30). Moreover, glycine and proline levels were lower in EMS group. Because it is 
essential to prevent muscle atrophy (31), lower levels of glycine may indicate increased glycine 
consumption for protecting muscles. In contrast, lower levels of proline may also indicate decreased 
level of catabolism because muscle atrophy increases proline levels (32). Overall, in our study, the 
levels of most amino acids were lower in the EMS group, with or without statistical significance, 
suggesting an attenuated catabolic response. However, our experiments on amino acids are at a 





Our study has several limitations. First, this study included a small sample size, especially in 
the analysis of physical function. Second, complete blinding could not be achieved. Investigators could 
not completely avoid seeing the intervention, and patients could understand the intervention or control. 
Thus, some bias may remain although the data analysis was blinded in a previously reported reliable 
method (10, 11). Third, as our study compared the effect of EMS added to the mobilization protocol 
with the mobilization protocol alone, the outcomes are associated with EMS application in combination 
with the mobilization protocol and not EMS alone. 
 
CONCLUSIONS 
In this trial, early application of EMS prevented upper and lower limb muscle atrophy in 
critical ill patients. EMS also attenuated proteolysis and decreased the length of hospitalization. Further 
research is required to determine if EMS improves physical function and long-term outcomes of 
critically ill patients. 
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FIGURE LEGENDS 
Figure 1. Flowchart of patients included in this study 
EMS = electrical muscle stimulation 
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Figure 2. Change in biceps brachii and rectus femoris muscle mass 
a. EMS prevented reduction of biceps brachii muscle thickness (p = 0.007) and cross-sectional area (p =
0.03). b. EMS prevented reduction of rectus femoris muscle thickness (p = 0.003) and cross-sectional 
area (p = 0.04). Data are presented as means and standard error. P values were derived from t-test. 
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TABLE 1. Patient Characteristics 
Variables EMS, n = 17 Control, n = 19 p 
Age, mean ± SD, y  73 ± 3 66 ± 3 0.09 
Gender (M/F) 12/5 12/7 0.64 
Body mass index (kg/m2) 23 ± 4 24 ± 4 0.33 
APACHE II 25 (20–31) 22 (19–30) 0.57 
SOFA, mean over the first 3 days 9 (6–12) 7 (5–10) 0.13 
Sepsis-3 criteria on admission, n (%) 8 (46) 11 (58) 0.51 
ICU admission reasons, n (%) 
Respiratory failure 6 (35) 6 (32) 
0.40 
Heart failure 2 (12) 1 (5) 
Neurologic 1 (6) 3 (16) 
Post-cardiac surgery 5 (29) 2 (11) 
Sepsis, nonrespiratory 2 (12) 4 (21) 
Others 1 (6) 3 (16) 
Comorbidities, n (%) 
Diabetes mellitus 4 (25) 6 (35) 0.52 
Cancer 0 (0) 1 (5) 0.32 
Medications, n (%) 
Catecholamine* 14 (82) 12 (63) 0.20 
Neuromuscular blocking agents† 0 (0) 0 (0) - 
Steroids‡ 6 (35) 6 (32) 0.81 
Aminoglycoside 0 (0) 1 (5) 0.34 
Opioids 14 (82) 14 (74) 0.53 
Sedatives§ 11 (65) 14 (74) 0.56 
Nutrition 
Days to enteral nutrition 2 (1–2) 2 (2–2) 0.42 
Calorie at day 5, kcal/kg 9.8 (8.8–15.8) 13.2 (8.8–21.9) 0.11 
Protein at day 5, g/kg 0.6 (0.4–0.7) 0.6 (0.4–0.8) 0.41 
EMS = electrical muscle stimulation, APACHE = Acute Physiology and Chronic Health 
Evaluation, SOFA = Sequential Organ Failure Assessment, IQR = interquartile range 
*Catecholamine (dopamine, dobutamine, noradrenaline, or adrenaline), †Neuromuscular blockers
with continuous use, ‡Steroids with intravenous or peroral use, §Sedatives (midazolam, propofol) 
Data were presented as median (IQR) unless otherwise indicated.  
TABLE 2. Secondary Outcomes 
Variables EMS, n = 17 Control, n = 19 p 
Functional outcomes (n = 8, 10)    
MRC score at day 5  55 (50–58) 52 (35–59) 0.53 
ICU-AW (%) at day 5  13% 40% 0.20 
IMS at discharge from the ICU 3 (1–4) 2 (1–3) 0.42 
Ventilator-free days, d 23 (19–25) 22 (10–24) 0.45 
ICU-free days, d 21 (12–23) 20 (9–23) 0.97 
length of hospitalization, d 23 (19–34) 40 (26–64) 0.04 
length of hospitalization (survivor), d 24 (20–32) 40 (29–55) 0.03 
After hospital discharge    
Home 3 4 
0.42 Transfer 11 11 
Death 3 4 
Amino acid level    
Day 1 to day 3 (n = 14, 17)    
BCAA, % 40.5 (−7.4 to 75.3) 71.5 (38.8 to 116.9) 0.04 
Glycine, % −23.4 (−54.5 to −0.6) 12.3 (−1.8 to 39.7) < 0.01 
Proline, % 2.6 (−43.4 to 48.3) 54.3 (−11.4 to 147.9) 0.04 
Day 1 to day 5 (n = 12, 15)    
BCAA, % 18.6 (−12.8 to 67.2) 21.6 (9.0 to 106.1) 0.59 
Glycine, % −37.3 (−40.8 to −16.1) 4.0 (−5.5 to 37.4) < 0.01 
Proline, % −11.0 (−28.6 to 25.4) 37.9 (−27.6 to 95.1) 0.26 
MRC = medical research council, ICU-AW = intensive care unit-acquired weakness, IMS = 
intensive care unit mobility scale, ICU = intensive care unit, BCAA = branched-chain amino acid, 
IQR = interquartile range 
Data were presented as median (IQR) unless otherwise indicated. 
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Mobilization level was decided according to patients’ neurological function (conscious or 
unconscious) and muscle strength. Passive range of motion was carried out for unconscious 
patients, whereas in conscious patients, the intensity was gradually increased to active resistance, 
sitting on the edge of bed, and ambulation. Mobilization level was limited in patients with 
hemodynamic or respiratory instability.  
 
Ultrasound measurement 
All scanning was done with patients supine and elbows and knees in passive extension. Generous 
amounts of contact gel were applied to avoid compression of the muscles by the transducer, and 
the transducer was placed perpendicular relative to the long axis of the limbs. A B-mode ultrasound 
with a linear transducer was used. Biceps brachii muscle was measured at two-thirds of the way 
between the acromion and the antecubital crease. Rectus femoris muscle was measured at midway 
between the anterior superior iliac spine and the proximal end of the patella. Biceps brachii muscle 
thickness (including the underlying brachialis muscle) was defined as the depth between the 
superficial fascia of the biceps brachii muscle and the uppermost part of the humerus, and cross-
sectional area of the biceps brachii muscle was measured by tracking the area in the transverse 
plane. Rectus femoris muscle thickness (including the underlying vastus intermedius muscle) was 
defined as the depth between the superficial fascia of the rectus femoris muscle and the uppermost 
part of the femur, and cross-sectional area of rectus femoris muscle was measured by tracking the 
area in the transverse plane.  
 
Physical assessment 
Consciousness was evaluated as adequate when patients respond to at least three of the five orders 
(“open/close your eyes,” “look at me,” “open your mouth and put out your tongue,” “nod your 
head,” and “raise your eyebrows”). In responsive patients, we evaluated MRC score including 
bilateral shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle 
dorsiflexors. 
 
Amino acid level 
The collected blood was immediately mixed with methanol with internal standard solution. High 
performance liquid chromatography and Milli-Q water (Millipore, Bedford, MA, USA) were 
added to the sample. The tube was centrifuged at 4°C for 5 minutes at 3150 rotations per minute. 
After the water layer was transferred into centrifuge filter tubes, the filtered sample was 
centrifuged again at 4°C for 4 hours at 9100 rotations per minute. Next, it was dried with vacuum 
centrifugal dryer for 2 hours and stored at −80°C. Finally, it was added to 50 μL of Milli-Q water 






TABLE S1. Reproducibility of Measurements 
CI = confidence interval 
Reproducibility was assessed for 36 patients at 72 measurements in rectus femoris muscle. The 
Pearson correlation coefficient and Bland-Altman plot were determined by using JMP statistical 
software version 13.1.0 (SAS Institute Inc., Cary, NC, USA).  
 
  
  Correlation coefficient  Bland-Altman 95% CI 
Variables r p  Bias 95% CI 
Intra-observer reproducibility      
Thickness      
Biceps brachii muscle 0.99 < 0.01  0.025 ± 0.081 −0.137 to 0.187 
Rectus femoris muscle 0.99 < 0.01  −0.024 ± 0.100 −0.223 to 0.175 
Cross-sectional area      
Biceps brachii muscle 0.99 < 0.01  −0.001 ± 0.046 −0.093 to 0.090 
Rectus femoris muscle 0.98 < 0.01  −0.086 ± 0.045 −0.177 to 0.004 
Inter-observer reproducibility      
Thickness      
Biceps brachii muscle 0.99 < 0.01  0.140 ± 0.105 −0.069 to 0.349 
Rectus femoris muscle 0.99 < 0.01  −0.058 ± 0.125 −0.307 to 0.191 
Cross-sectional area      
Biceps brachii muscle 0.99 < 0.01  −0.015 ± 0.055 −0.126 to 0.095 
Rectus femoris muscle 0.98 < 0.01  −0.103 ± 0.054 −0.211 to 0.005 
TABLE S2. Amino Acid Level 
Variables Group 
Percentage change from Day 1 to Day 3 or 5 
Day 3 p Day 5 p 
Glycine 
Control 12.3 (−1.8 to 39.7) 
< 0.01 
4.0 (−5.5 to 37.4) 
< 0.01 
EMS −23.4 (−54.5 to −0.6) −37.3 (−40.8 to −16.1) 
Alanine 
Control 6.5 (−26.7 to 71.3) 
0.36 
−3.6 (−37.1 to 70.3) 
0.53 
EMS −7.6 (−26.2 to 36.8) 0.8 (−38.1 to 22.2) 
Serine 
Control 46.3 (14.8 to 85.0) 
0.21 
29.8 (−8.4 to 57.9) 
0.86 
EMS 29.3 (−6.2 to 60.5) 22.3 (−6.8 to 57.4) 
Proline 
Control 54.3 (−11.4 to 147.9) 
0.04 
37.9 (−27.6 to 95.1) 
0.26 
EMS 2.6 (−43.4 to 48.3) −11.0 (−28.6 to 25.4) 
Valine 
Control 59.5 (30.9 to 98.0) 
0.07 
27.2 (14.7 to 68.0) 
0.53 
EMS 31.5 (−21.5 to 65.7) 20.5 (−13.7 to 60.3) 
Threonine 
Control 97.4 (2.4 to 206.7) 
0.18 
92.8 (−17.7 to 209.1) 
0.31 
EMS 32.7 (−15.7 to 108.9) 26.4 (−9.8 to 95.2) 
Cysteine 
Control 74.7 (7.1 to 143.8) 
0.07 
59.4 (−15.3 to 128.9) 
0.70 
EMS −12.7 (−26.4 to 29.9) 17.1 (−19.6 to 115.6) 
Isoleucine 
Control 125.4 (55.6 to 235.1) 
0.10 
50.5 (5.0 to 340.2) 
0.81 
EMS 65.4 (−16.3 to 147.9) 33.2 (1.9 to 174.8) 
Leucine 
Control 61.8 (46.3 to 144.4) 
0.14 
16.9 (−3.5 to 152.6) 
0.81 
EMS 59.8 (15.0 to 81.0) 8.1 (−12.1 to 66.9) 
Asparagine 
Control 38.4 (7.8 to 62.5) 
0.08 
25.9 (−3.2 to 39.9) 
0.77 
EMS 16.9 (−15.2 to 34.2) 11.8 (−13.4 to 44.0) 
Aspartic acid 
Control −0.1 (−18.6 to 27.4) 
0.81 
9.8 (−28.0 to 29.7) 
0.31 
EMS −5.2 (−24.7 to 47.8) 22.5 (−16.3 to 48.7) 
Glutamine 
Control 19.3 (−7.6 to 29.2) 
0.25 
−4.7 (−28.2 to 48.7) 
0.63 
EMS 4.1 (−34.5 to 35.1) −3.1 (−32.8 to 37.1) 
Lysine 
Control 129.6 (50.1 to 178.2) 
0.10 
108.4 (15.5 to 175.3) 
0.20 
EMS 55.1 (−35.5 to 147.9) 39.9 (3.3 to 105.3) 
Glutamic acid 
Control −3.3 (−19.1 to 32.8) 
0.58 
7.4 (−16.9 to 27.2) 
0.70 
EMS −9.0 (−25.5 to 14.6) −0.9 (−31.8 to 46.1) 
Methionine 
Control 114.3 (33.0 to 176.3) 
0.37 
45.6 (−10.5 to 192.5) 
0.92 
EMS 15.8 (−15.5 to 139.3) 49.7 (−24.7 to 127.6) 
Histidine 
Control 12.4 (2.6 to 28.3) 
0.87 
6.2 (−33.6 to 14.3) 
0.66 
EMS 14.0 (−18.1 to 56.0) −5.0 (−28.4 to 21.9) 
Phenylalanine 
Control 31.2 (5.0 to 44.2) 
0.94 
6.8 (−16.4 to 24.7) 
0.63 
EMS 20.1 (1.2 to 84.1) 9.5 (−24.0 to 71.4) 
Arginine 
Control 73.6 (29.8 to 242.8) 
0.23 
61.4 (10.4 to 191.4) 
0.53 
EMS 63.8 (−45.7 to 147.8) 41.6 (6.8 to 144.6) 
Tyrosine 
Control 48.6 (13.0 to 100.7) 
0.18 
31.7 (−8.9 to 62.6) 
0.63 
EMS 6.5 (−14.0 to 61.5) 26.3 (−19.9 to 57.6) 
Tryptophan 
Control 22.3 (−2.8 to 108.2) 
0.38 
16.9 (−18.8 to 82.0) 
0.85 
EMS 14.4 (−18.9 to 59.8) 15.4 (−18.7 to 74.7) 
BCAA 
Control 71.5 (38.8 to 116.9) 
0.04 
21.6 (9.0 to 106.1) 
0.59 
EMS 40.5 (−7.4 to 75.3) 18.6 (−12.8 to 67.2) 
EMS = electrical muscle stimulation, BCAA = branched-chain amino acid 
Amino acid level was assessed in EMS and control (14 and 17 on day 3, 12 and 15 on day 5). The 
Mann-Whitney test was used for the comparison.  
 
